

## Coherus BioSciences Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 02-Aug-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Product Portfolio Summary..... 12

Product Portfolio Drugs..... 16

[Return to Table of Contents](#)

# Coherus BioSciences Inc

## COMPANY OVERVIEW

Company Name	Coherus BioSciences Inc
Parent Company Name	Coherus BioSciences Inc
Website	<a href="http://www.coherus.com/">http://www.coherus.com/</a>
Country	US
Number of Drugs in Active Development	8
Number of Inactive Drugs	0
Number of Patents as Owner	9
Number of Patents as Third Party	0
Number of Deals	2
Key Indications	Unidentified indication,Rheumatoid arthritis,Psoriasis,Inflammatory disease,Febrile neutropenia,Hematological neoplasm,Ankylosing spondylitis,Psoriatic arthritis,Asthma,Atopic dermatitis,Cachexia,Chronic obstructive pulmonary disease,Crohns disease,Hepatitis C virus infection
Key Target-based Actions	TNF alpha ligand inhibitor,TNF antagonist,Type II TNF receptor modulator,B-lymphocyte antigen CD20 inhibitor,GCSF ligand,GCSF receptor agonist
Key Technologies	Biological therapeutic,Biosimilar product,Protein recombinant,Parenteral formulation unspecified,Subcutaneous formulation,Protein fusion,Liquid formulation,Monoclonal antibody human,Chimeric monoclonal antibody,Infusion,Intravenous formulation,PEGylated formulation,Systemic formulation unspecified

## COMPANY PROFILE

### SUMMARY

Coherus BioSciences was incorporated in Delaware in September 2010 under the name BioGenerics Inc and subsequently changed its name to Coherus BioSciences Inc in April 2012. It is a biopharmaceutical company specializing in biosimilars in the field of oncology and inflammation.

### COMPANY LOCATION

Coherus is based in San Francisco, CA.

### FINANCIAL

In March 2015, the company announced an underwritten public offering of \$100 million of common stock shares; underwriters were to be granted a 30-day option to purchase a further \$15 million of shares. Later that month, Coherus priced the underwritten public offering of 4,137,931 shares of its common stock at a price of \$29.00 per share. The underwriters were granted a 30-day option to purchase up to an additional 620,689 shares of common stock at the public offering price. The offering was expected to close on or about April 07, 2015.

In November 2014, the company priced its IPO of 6,296,300 shares of its common stock at \$13.50 per share, trading under ticker symbol 'CHRS', and granted the underwriters a 30-day option to purchase up to 944,445 additional common shares at the offering price. At that time, the offering was expected to close on November 12, 2014. In November 2014, the company closed the IPO of 6,803,702 of its common stock shares and included a purchase of 507,402 shares of the company's common stock by the underwriters with an option to purchase additional shares. At that time, the company expected the net proceeds to be approximately \$81.5 million.

In May 2014, the company raised \$55 million through a series C financing.

[Return to Table of Contents](#)



COMPANY FINANCIALS

SHARE INFORMATION

Close Price (USD)	35.08
Change (USD)	1.36 (4.03%)
Previous Close Price (USD)	33.72
Volume	147,150
52-Week High (USD)	38.10
52-Week Low (USD)	12.27
Date	31-Jul-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	33,701,017
Current Market Capitalization	1,341,854,165
EPS (Date Reported)	-10.64346

STOCK PERFORMANCE



MAJOR SHAREHOLDERS

[Return to Table of Contents](#)


Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
BlackRock Institutional Trust Company, N.A.	Investment Advisor	United States	639,573	1.69	435,880	2.14	30-Jun-2015
iShares Russell 2000 ETF	Mutual Fund	United States	367,638	0.97	249,288	2.11	30-Jun-2015
Fidelity Blue Chip Growth Fund	Mutual Fund	United States	367,600	0.97	294,100	4	30-Jun-2015
Jennison Associates LLC	Investment Advisor/Hedge Fund	United States	345,666	0.91	345,666	1	30-Jun-2015
Prudential Jennison Health Sciences Fund	Mutual Fund	United States	345,666	0.91	345,666	1	30-Jun-2015
Vanguard Total Stock Market Index Fund	Mutual Fund	United States	335,121	0.89	205,998	1.6	30-Jun-2015
JPMorgan Small Cap Growth Fund	Mutual Fund	United States	330,514	0.87	3,309	0.01	31-May-2015
Fidelity OTC Portfolio	Mutual Fund	United States	267,626	0.71	267,626	1	30-Jun-2015
Fidelity Contrafund	Mutual Fund	United States	211,890	0.56	211,890	1	30-Jun-2015
iShares Russell 2000 Growth ETF	Mutual Fund	United States	180,299	0.48	131,860	2.72	30-Jun-2015
Fidelity Series Blue Chip Growth Fund	Mutual Fund	United States	140,200	0.37	108,600	3.44	30-Jun-2015
JPMorgan Dynamic Small Cap Growth Fund	Mutual Fund	United States	137,183	0.36	-13,327	-0.09	31-May-2015
TIAA-CREF Mid Cap Growth Fund	Mutual Fund	United States	119,609	0.32	119,609	1	31-May-2015
Vanguard Extended Market Index Fund	Mutual Fund	United States	100,570	0.27	82,365	4.52	30-Jun-2015
Fidelity Trend Fund	Mutual Fund	United States	90,249	0.24	90,249	1	30-Jun-2015
JPMorgan U.S. Small Company Fund	Mutual Fund	United States	76,900	0.2	9,400	0.14	31-May-2015
Carnegie Asset Management Fondsmglersekskab A/S	Investment Advisor	Denmark	60,000	0.16	60,000	1	30-Jun-2015
iShares Micro-Cap ETF	Mutual Fund	United States	56,857	0.15	40,435	2.46	30-Jun-2015

[Return to Table of Contents](#)



Principal SmallCap Growth Fund I	Mutual Fund	United States	55,163	0.15	0	0	30-Jun-2015
Fidelity Advisor New Insights Fund	Mutual Fund	United States	54,100	0.14	54,100	1	30-Jun-2015

FINANCIAL PERFORMANCE



	2012	2013	2014		
Sales (USD M)	1.899	2.751	31.106		
Operating Income (USD M)	-38.518	-35.993	-64.682		
Net Income (USD M)	-33.018	-53.635	-87.133		

## Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2015 Q1	5.81	-36.748	-40.725
2014 Q4	6.493	-26.56	-29.134
2014 Q3	16.052	-6.423	-7.872
2014 Q2	4.965	-17.938	-24.957
2014 Q1	3.596	-13.761	-25.17
2013 Q4	1.232	-10.487	-14.591
2013 Q3	0.506	-6.783	-21.473
2013 Q2	0.507	-9.284	-8.709
2013 Q1	0.506	-9.439	-8.862

## BALANCE SHEET

### Assets (USD M)

	2012	2013	2014		
Cash & Short Term Investments	14.598	39.604	150.452		
Inventories - Total	0	0	0		
Current Assets - Total	24.799	45.677	179.136		
Property, Plant And Equipment - Net	1.605	1.743	4.472		
Other Assets - Total	0.006	0.027	3.613		
Total Assets	26.533	47.447	187.221		

### Liabilities (USD M)

	2012	2013	2014		
Accounts Payable	2.209	3.302	8.778		
Short Term Debt & Current Portion Of Long Term Debt	0	4.203	0		
Current Liabilities - Total	11.253	53.701	51.783		
Long Term Debt	0	0	0		
Other Liabilities	0.012	7.561	28.782		
Total Liabilities	17.341	89.829	120.464		

[Return to Table of Contents](#)



## Stockholders Equity (USD M)

	2012	2013	2014		
Minority Interest	0	0	-0.044		
Preferred Stock	58.282	58.282	0		
Common Stock	0.001	0.001	0.003		
Treasury Stock	0		0		
Total Liabilities & Shareholders' Equity	26.533	47.447	187.221		

## FORECASTS

### EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-3.01	-3.01	-3.2
31-Dec-2016	-4.08	-4.08	-2.54
31-Dec-2017	-3	-3	-2.73

### Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015	0	-2.8	-112	27.5
31-Dec-2016	0	-4.26	-161.5	29
31-Dec-2017			-130	106


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

## Drugs by Indication Table

Indication	Active	Inactive	Total
Unidentified indication	4	0	4
Immune disorder	2	0	2
Dermatological disease	2	0	2
Musculoskeletal disease	2	0	2
Hematological disease	2	0	2
Inflammatory disease	2	0	2
Neoplasm	1	0	1

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



## Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Phase 1 Clinical	3
Discovery	4

[Return to Table of Contents](#)

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	2	0	0	0	2

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Immune disorder	4	4
Dermatological disease	3	3
Musculoskeletal disease	2	2
Inflammatory disease	2	2

### Trials by Phase

Phase	Ongoing	All
Phase 3	4	4
Phase 1	2	3
Phase not specified	0	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Immune disorder	4	0	4
Musculoskeletal disease	3	0	3
Neoplasm	1	0	1
Neurological disease	1	0	1
Nutritional disorder	2	0	2
Respiratory disease	3	0	3

[Return to Table of Contents](#)



Infectious disease	2	0	2
Cardiovascular disease	1	0	1
Gastrointestinal disease	3	0	3
Genitourinary disease	2	0	2
Hematological disease	1	0	1
Degeneration	1	0	1
Dermatological disease	4	0	4
Inflammatory disease	4	0	4
Gynecology and obstetrics	1	0	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### etanercept biosimilar, Coherus BioSciences/Daiichi Sankyo/Baxalta

<b>Drug Name</b>	etanercept biosimilar, Coherus BioSciences/Daiichi Sankyo/Baxalta
<b>Key Synonyms</b>	etanercept
<b>Originator Company</b>	Coherus BioSciences Inc
<b>Active Companies</b>	Coherus BioSciences Inc, Baxalta Inc, Daiichi Sankyo Co Ltd
<b>Inactive Companies</b>	Baxter International Inc
<b>Highest Status</b>	Phase 3 Clinical
<b>Active Indications</b>	Rheumatoid arthritis, Psoriasis, Inflammatory disease
<b>Target-based Actions</b>	Type II TNF receptor modulator, TNF alpha ligand inhibitor, TNF antagonist
<b>Other Actions</b>	Anti-inflammatory, TNF binding agent
<b>Technologies</b>	Biosimilar product, Biological therapeutic, Liquid formulation, Subcutaneous formulation, Protein fusion
<b>Last Change Date</b>	09-Jul-2015

### CHS-001

<b>Drug Name</b>	CHS-001
<b>Key Synonyms</b>	
<b>Originator Company</b>	Coherus BioSciences Inc
<b>Active Companies</b>	Coherus BioSciences Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Unidentified indication
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target
<b>Technologies</b>	Biosimilar product, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant
<b>Last Change Date</b>	24-Jul-2014

[Return to Table of Contents](#)





### adalimumab biosimilar, Coherus

<b>Drug Name</b>	adalimumab biosimilar, Coherus
<b>Key Synonyms</b>	adalimumab
<b>Originator Company</b>	Coherus BioSciences Inc
<b>Active Companies</b>	Coherus BioSciences Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Psoriasis, Rheumatoid arthritis
<b>Target-based Actions</b>	TNF alpha ligand inhibitor
<b>Other Actions</b>	TNF binding agent, Anti-inflammatory
<b>Technologies</b>	Biosimilar product, Biological therapeutic, Parenteral formulation unspecified, Systemic formulation unspecified, Protein recombinant, Monoclonal antibody human
<b>Last Change Date</b>	25-Jul-2015

### pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences

<b>Drug Name</b>	pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences
<b>Key Synonyms</b>	pegfilgrastim
<b>Originator Company</b>	Coherus BioSciences Inc
<b>Active Companies</b>	Coherus BioSciences Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Febrile neutropenia
<b>Target-based Actions</b>	GCSF receptor agonist, GCSF ligand
<b>Other Actions</b>	Hematopoietic stimulant, Neutrophil stimulator
<b>Technologies</b>	Biosimilar product, PEGylated formulation, Biological therapeutic, Subcutaneous formulation, Protein recombinant
<b>Last Change Date</b>	18-Mar-2015

[Return to Table of Contents](#)



## rituximab biosimilar, Coherus BioSciences/Daiichi Sankyo

<b>Drug Name</b>	rituximab biosimilar, Coherus BioSciences/Daiichi Sankyo
<b>Key Synonyms</b>	rituximab
<b>Originator Company</b>	Coherus BioSciences Inc
<b>Active Companies</b>	Coherus BioSciences Inc, Daiichi Sankyo Co Ltd
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Hematological neoplasm
<b>Target-based Actions</b>	B-lymphocyte antigen CD20 inhibitor
<b>Other Actions</b>	Anticancer monoclonal antibody
<b>Technologies</b>	Biosimilar product, Biological therapeutic, Intravenous formulation, Infusion, Protein recombinant, Chimeric monoclonal antibody
<b>Last Change Date</b>	21-Jan-2014

## CHS-002

<b>Drug Name</b>	CHS-002
<b>Key Synonyms</b>	
<b>Originator Company</b>	Coherus BioSciences Inc
<b>Active Companies</b>	Coherus BioSciences Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Unidentified indication
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target
<b>Technologies</b>	Biosimilar product, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant
<b>Last Change Date</b>	24-Jul-2014

[Return to Table of Contents](#)

**CHS-003**

<b>Drug Name</b>	CHS-003
<b>Key Synonyms</b>	
<b>Originator Company</b>	Coherus BioSciences Inc
<b>Active Companies</b>	Coherus BioSciences Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Unidentified indication
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target
<b>Technologies</b>	Biosimilar product, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant
<b>Last Change Date</b>	24-Jul-2014

**CHS-004**

<b>Drug Name</b>	CHS-004
<b>Key Synonyms</b>	
<b>Originator Company</b>	Coherus BioSciences Inc
<b>Active Companies</b>	Coherus BioSciences Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Unidentified indication
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target
<b>Technologies</b>	Biosimilar product, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant
<b>Last Change Date</b>	24-Jul-2014

[Return to Table of Contents](#)


This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

